Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC. The ...
Availability of estradiol transdermal patches is variable despite ongoing market presence, prompting FDA engagement with all 6 manufacturers to improve continuity of patient therapy. Heightened demand ...
A recap of the FDA submissions and regulatory decisions in urology from June 2026. Welcome to Urology Times’® monthly FDA update! June 2026 brought a wave of regulatory developments across the urology ...
The following FAQs highlight key recommendations and practical takeaways from the 2026 AUA/SUO Advanced Prostate Cancer Guideline. Two overarching themes define the 2026 amendment: the consolidation ...
A comprehensive guide to the practice-changing, paradigm-shifting studies across benign urologic conditions. At the 2026 Annual Meeting of the American Urological Association in Washington, DC, the P2 ...
A comprehensive guide to the practice-changing, paradigm-shifting studies across urologic oncology. Urologists will soon gather in Washington, DC, for the 2026 Annual Meeting of the American ...
Pre-operative counseling should frame vasectomy as intended permanent contraception, individualized to reproductive goals, and can be delivered virtually or in person while directly addressing ...
FDA 510(k) clearance enables use of external neuromuscular stimulation to strengthen pelvic floor musculature and improve bladder control in men with post-prostatectomy incontinence. Daily home ...
VYBRIQUE is a sildenafil oral film formulated for discreet, water-free administration, aiming to reduce use barriers for patients for whom privacy and convenience influence ED treatment adherence. A ...
In this opening segment, Richard Wassersug, PhD, and Paul F. Schellhammer, MD, FACS, discuss the origins, goals, and challenges of the Estradiol Initiative. In this opening segment, Wassersug and ...
A recap of the FDA submissions and regulatory decisions in urology from December 2025. Welcome to Urology Times’® monthly FDA update! The year wrapped up with a flurry of regulatory approvals across ...
Panelists discuss how real-world comparisons of apalutamide and enzalutamide suggest survival trends influenced by tolerability, adherence, and patient selection rather than intrinsic drug differences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results